| Textual Information(1) |
1.The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2.The National Pharmaceutical Pricing Authority (“NPPA”) issued several demand notices to the Company commencing from the year 1998 seeking recovery of alleged overcharge regarding scheduled drugs under the Drugs (Prices Control) Orders-1995 (“DPCO”). In 1999 and 2000, the Company filed writ petitions before the Hon’ble Bombay High Court (“Bombay HC”) challenging inclusion of certain drugs under DPCO and challenging the demand notices issued by NPPA demanding payment of alleged overcharged amounts. On 31st August, 2001, by way of its common judgment, the Bombay HC decided the writ petitions in favor of the Company, thereby holding that these drugs do not fall within the purview of DPCO and also quashed the demand notices raised by NPPA. The NPPA appealed the order to the Hon’ble Supreme Court (“SC”). On 1st August, 2003, SC set aside the Bombay HC judgment and remanded the matter to the Bombay HC for being considered afresh by it. Further, the SC stayed recovery of 50% of the alleged overcharged amounts subject to payment of the remaining 50% of the alleged overcharged amounts pending fresh determination by the Bombay HC. Accordingly, in terms of SC’s Judgment the Company deposited an amount of Rs 175.08 Crores with NPPA, representing 50% of the alleged overcharged amounts in respect of demand notices raised till 2003. Post 2003, the Company continued to receive demands (“Subsequent demands”) alleging overcharging. These demands included several duplicate demands. In 2019, the Company applied to the Bombay HC to amend its pleadings to include: (i) subsequent demands (ii) take on record the NPPA/ Government of India’s RTI response on unavailability of any records pertinent to and what should have been the basis for inclusion of these drugs under the DPCO (iii) deduction of trade margin of 16% from outstanding demands (as having not accrued to the Company, as manufacturer) basis the Allahabad HC’s TC Healthcare judgment (iv) re-calculation of interest from the due date of demand notice and (v) duplication of several demands. The Bombay HC vide order dated 23rd February, 2024 allowed the amendment conditional upon the Company depositing 50% of the subsequent demands raised. The Company appealed the Bombay HC order in a special leave petition before the SC. On 19th April, 2024, the SC was pleased to issue notice and the matter is pending to be heard further. Without prejudice to the Company’s position of no amount being due towards the alleged overcharge (principal) or consequential interest, on 15th July, 2025 the Company has voluntarily deposited with the NPPA an additional amount of Rs 27.07 Crores towards the principal against certain demand notices. The Company has reviewed all the notices/communications received which are attributable to the Company and are under litigation. After removing duplications as indicated above, the amount covered by the notices/communications aggregates to Rs 2,011 Crores with the principal of Rs 863 Crores and interest of Rs 1,148 Crores. The above demand notices do not include certain demand notices, jointly addressed to Okasa Pharma Private Limited or Okasa Limited (related parties and promoter group companies, collectively “Okasa), and the Company. These pertain to products manufactured by Okasa and marketed by Cipla. The Company responded to these demand notices (amounting to Rs 9.96 Crores), stating that it is not the manufacturer and therefore not liable. These demand notices are also subject matter under Business Transfer Agreement between Okasa and Cipla’s subsidiary which excludes the DPCO liability as part of the business transferred by Okasa to the subsidiary. Further, Okasa has independently challenged these demand notices before the Hon’ble Bombay HC. The Company has been legally advised that it expects a favourable outcome in respect of these matters and therefore no provision is considered necessary in respect of the aforementioned demand notices received till date including demand notices addressed singly/ jointly w.r.t transactions with Okasa. 3.The paid-up equity share capital stands increased to Rs 161.57 Crores (80,78,45,316 equity shares of face value Rs 2 each) upon allotment of 54,903 equity shares and 7,782 equity shares of Rs 2 each pursuant to ESOS 2013-A and “Cipla ESAR Scheme 2021” respectively during the quarter ended 30th June, 2026. 4.Effective 21st November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. Pursuant to the Group's assessment performed as at 31st December, 2025, the Group recognized an incremental gratuity liability arising from past service cost and an increase in leave liability aggregating Rs 275.91 Crores, primarily due to the revised definition of “wages” applicable to employees and contract labour. Considering the materiality and non-recurring nature of this change, the Group has presented such incremental expenses under “Exceptional Item” in the financial results. 5.The unaudited standalone financial results for the quarter ended 30th June, 2026 are available on the Company’s website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com. 6.Operating segment information is presented in a manner consistent with the internal reporting reviewed by the Group’s Chief Operating Decision Maker (“CODM”) for the purpose of allocating resources and assessing performance. The CODM of the Group is the Chief Executive Officer, who is responsible for making strategic decisions. During the year ended 31st March 2026, the Group reassessed its operating segments consequent to a change in the CODM. Based on this reassessment, the Group has determined that it operates as a single operating segment, namely Pharmaceutical and related products. Accordingly, the comparative information for the previous year has been restated, wherever necessary, to reflect the Group as operating under a single reportable segment, in accordance with Ind AS 108 – Operating Segments. 7.During the quarter and year ended 31st March 2026, the group has recorded an impairment of Rs 42.02 Crores in the financial results in respect of associates, on account of change in certain business conditions and market dynamics. 8.The Board of Directors of the Company, at its meeting held on 19th March 2026, approved the Scheme of Amalgamation of Inzpera Healthsciences Limited, a wholly owned subsidiary of the Company (the “Transferor Company”), with Cipla Limited (the “Transferee Company” or the “Company”). The Scheme of Amalgamation is subject to the necessary approvals required under the Companies Act, 2013, including the approval of the Hon’ble National Company Law Tribunal (“NCLT”), Mumbai. The Company has filed the Scheme with the Hon’ble NCLT and its approval is awaited. 9.Effective 1st April, 2026, the Group presents certain marketing and promotional expenditures as a reduction from Revenue from Operations. The Group believes that this presentation provides more relevant information on the Group’s financial performance. In the comparative periods, these amounts were presented under Sales promotion expenses within Other Expenses and amounted to Rs 115.24 Crores, Rs 145.13 Crores and Rs 528.29 Crores for the quarter ended 30th June, 2025, quarter ended 31st March, 2026 and year ended 31st March, 2026, respectively. This change relates solely to presentation and has no impact on Profit for the period/year, Earnings per Share, Total Equity or Cash Flows. 10.The figures for the quarter ended 31st March, 2026 is the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 11.The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 23rd July, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion. |